Data Support In-Hospital Start of SGLT2 Inhibitors for HF
MADRID —– SGLT2 inhibitors can be added to the list of guideline-directed medical therapies for heart failure that are best initiated before hospital discharge, according to a meta-analysis of randomized trials.
This meta-analysis included data from DAPA ACT HF-TIMI 68, the most recently completed trial of dapagliflozin in patients hospitalized for heart failure. Although this trial missed its primary composite endpoint of a reduction in cardiovascular death or worsening heart failure at 2 months, the preplanned meta-analysis showed significant improvements in outcome, including a reduction in all-cause death, according to David D. Berg, MD, MPH, of Brigham and Women’s Hospital in Boston.
The investigator-initiated, multinational randomized DAPA ACT HF-TIMI 68 trial adds SGLT2 inhibitors to the list of guideline-directed medical therapies for heart failure that should be started in the hospital, said Berg, who served as principal investigator for the trial.
نظر دهید